Absci

We’re excited to introduce Origin-1: a generative AI platform for de novo antibody design against "zero-prior" epitopes. Origin-1 has been successfully validated against four targets: COL6A3, AZGP1, CHI3L2, and IL36RA Key Highlights: -Fewer than 100 design attempts per target -Binding, developability, and ~100 nM functional potency confirmed across 5+ -orthogonal assays -Atomic accuracy confirmed by cryo-EM Our approach addresses a critical challenge in therapeutic discovery: designing antibodies for "zero-prior'"epitopes, which we define as target sites lacking structural data from reported antibody-antigen or protein-protein complexes involving the target. To our knowledge, this is the first demonstration of de novo design of full-length monoclonal antibodies (mAbs) against "zero-prior" epitopes with atomically accurate complex structures and functional activity. Read the preprint: absci.com/denovo/ Access our data: github.com/AbSciBio/origi…

It started in a 400 sq. ft. basement lab and a deeply held belief that the future of health lies in merging human ingenuity with machine intelligence. Today, that belief blossomed into an industry-leading AI platform pioneering a new era of medicine. Our Founder and CEO, @SeanRMcClain, will be taking the stage as a TEDxPortland Year 14 Speaker! Hear his vision for a world that moves beyond symptom management to engineering lifesaving medicines and cures. Share this moment with us Saturday, April 11: lnkd.in/gFc2S94hhttps:…

"AMD is helping Absci really push that frontier of AI drug discovery." - @Abscibio Founder and CEO, @SeanRMcClain shares a deeper dive into our collaboration to impact healthcare through AI.

Advanced Insights: Season 2 Rewind Hear Advanced Insights host Mark Papermaster and @SeanRMcClain, Founder and CEO of @abscibio, dive into how AI is completely disrupting the drug discovery process. With AI applications, biotechnology organizations, and eventually big pharma companies, can drastically reduce the time and cost investments required to bring groundbreaking drugs to market. Check out the full episode here youtube.com/watch?v=-MGp6h…

Advanced Insights: Season 2 Rewind Join AMD CTO Mark Papermaster and Dan Rabinovitsj, VP of Infrastructure at @Meta, as they discuss the complexity of deploying AI at the edge, and the importance of reliability. Watch the full episode here: bit.ly/4j2ICXv

During the #CES2026 Keynote address, @LisaSu was joined by @Abscibio CEO @SeanRMcClain, @Illumina CEO Jacob Thaysen, and @AstraZeneca Head of Molecular AI, Ola Engkvist, in a fireside chat to discuss applying AI to real-world healthcare challenges.

Work and personal life just collided in a surprising & cool way. In @LisaSu's keynote at #CES2026, @seanmcclain shared the work Absci is doing to advance drug development using generative AI, specifically for #Endometriosis & Alopecia. 3 weeks ago I had surgery for Endo. Currently there is no cure. The procedure I had is one of a few options to manage symptoms. Thank you @abscibio for your work in this space, and thank you #AMD for supporting it! 🙏 youtube.com/clip/UgkxeoiZa…

Proud to work with @landondonovan to shine a light on the significant impact of hair loss and the need for better therapies for patients. Learn more about Absci's research in AGA at our KOL Seminar: investors.absci.com/events/event-d…

Hair update: So many of you have reached out wanting to know what the latest is for hair-loss. I've teamed up with Absci who is doing really incredible clinical research to completely change hair-loss forever. @abscibio @SeanRMcClain

From AI-designed HIV antibodies to regenerative treatments for hair loss, @abscibio's @SeanRMcClain joins @CathieDWood and @wintonARK on FYI to share how generative AI is transforming drug discovery. ark-invest.com/podcast/curing…

Hair isn’t just about appearance — it’s about identity. For many, hair loss affects confidence and how we show up in the world. That’s why I’m proud of what our @abscibio team is doing with ABS-201, our AI-designed biologic now preparing for first-in-human trials in Australia 🇦🇺 ABS-201 targets the prolactin receptor to reactivate dormant follicles — a potential once-quarterly injection that we believe will offer an alternative to daily pills or topicals. Built in ~24 months using our gen AI drug design platform, it shows what’s possible when we design new biologics with speed, precision, and purpose. Grateful to collaborate with Drs. Anthony Rossi, David Goldberg, Rodney Sinclair, and Prof. Ralf Paus — their expertise has been instrumental. Read more about the science behind ABS-201 in Popular Mechanics 👇 popularmechanics.com/science/health…

Absci is teaming up with @OracleCloud and @AMD to accelerate AI-driven drug discovery. Our collaboration work, including with AMD's next-gen Instinct MI355X GPUs, further boosts the performance and scalability of our AI Drug Creation Platform whether its scaling molecular-dynamics simulations or end-to-end antibody design. Release: globenewswire.com/news-release/2…

We’re excited to expand our collaboration with @AlmirallUS who has now elected a second target in our AI Drug Creation collaboration. ✅ Builds on Absci's successful de novo design for difficult-to-drug target in first program of collaboration ✅ Up to ~$650 M in milestones plus royalties across the two programs ✅ Shared commitment to accelerating innovation for patients suffering from skin diseases Read the full announcement: lnkd.in/drCjk6Je #GenerativeAI #DrugDiscovery #Dermatology #Biotech

Our first AI-designed antibody is already in the clinic and our second is well underway—now we’re seeking a  Medical Director, Clinical Development to help lead the next wave. Join our mission to create better biologics for patients, faster. Learn more: absci.com/job/?id=661789…

Love the question @pmarca. Thick, dark hair regrowth in monkeys and mice👇 ABS-201 human interim efficacy readout expected next year. Hair’s next big moment 🛰️ @elonmusk @davidasinclair @abscibio $absi

Can’t join us in person? Read our case study on ABS-201, a potential category-defining treatment for male and female pattern hair loss designed using generative AI. absci.com/abs-201-case-s… #Absci #AI #Biologics #DrugDiscovery

We’re pleased to be presenting at the American Academy of Dermatology (AAD) Innovation Academy 2025 next week. Join us for our presentation “Prolactin Receptor Antagonist ABS-201: An AI-Designed Therapy for Androgenetic Alopecia”: aad.org/member/meeting… #AADInnovation2025

@abscibio becomes clinical-stage company with clinical trial initiation ddw-online.com/absci-becomes-… #ClinicalTrial

See why we are excited about the potential ABS-101, Absci’s first AI-designed biologic to enter the clinic, has to treat IBD, and get an update on some of the other assets in our growing pipeline in this deep dive with @GENbio's @AlexWestchester. #AI #DrugDiscovery #Biologics